Scholar Rock Holding Corporation Announces EMBRAZE Trial Results
SRRK
Published on 06/18/2025 at 09:50
Scholar Rock Holding Corporation and Scholar Rock Inc. (collectively, Scholar Rock), including without limitation, Scholar Rock expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab and its preclinical programs, including SRK-439, and indication selection and development timing, including the timing of any regulatory submissions or approvals, the therapeutic potential, clinical benefits and safety of any product candidates, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, expectations regarding commercial launch timing in the US and in Europe, expectations regarding the ability of any product candidates to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. These risks and uncertainties include, without limitation, that preclinical and clinical data, including whether the results from the Phase 2 EMBRAZE trial may not be predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate; Scholar Rock ability to manage expenses or provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock ability to obtain, maintain and protect its intellectual property; and Scholar Rock dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock subsequent filings with the Securities and Exchange Commission.